Cover Image

Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism

Objective: Cost-effectiveness analysis of a 6-month treatment of apixaban (10 mg/12h, first 7 days; 5 mg/12h afterwards) for the treatment of the first event of venous thromboembolism (VTE) and prevention of recurrences, versus low-molecular-weight heparins/vitamin K antagonists treatment (LMWH/VKA)...

Full description

Saved in:

Bibliographic Details
Main Authors:	Isabel Elías (Author), Itziar Oyagüez (Author), Luis Antonio Alvarez-Sala (Author), Fernando García-Bragadoa (Author), Andrés Navarro (Author), Paloma González (Author), Fernando de Andrés-Nogales (Author), Javier Soto (Author)
Format:	Book
Published:	Elsevier, 2016-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

CURRENT TREATMENT OF VENOUS THROMBOEMBOLIC COMPLICATIONS WITH ANTICOAGULANTS: APIXABAN
by: I. S. Yavelov
Published: (2015)

Apixaban therapy in a pregnant woman with heparin-induced thrombocytopenia and venous thromboembolic events caused by congenital antithrombin deficiency: A case report
by: Mayuko Komori, et al.
Published: (2020)

Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery
by: Werth S, et al.
Published: (2012)

Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events
by: O. V. Shatalova
Published: (2015)

Clinical and economic analysis of the use of apixaban for the treatment of venous thromboembolic events
by: O. V. Shatalova
Published: (2015)

Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence
by: Zalpour A, et al.
Published: (2014)

Apixaban role in the treatment of venous thromboembolic complications in patients with active cancer
by: E. P. Panchenko
Published: (2020)

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes
by: Alex C Spyropoulos, et al.
Published: (2008)

Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World Studies
by: Olivia Wu, et al.
Published: (2022)

Efficacy and safety of novel oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolism
by: Maodi Xu, et al.
Published: (2018)

Pharmacoeconomic evaluation of apixaban use for the treatment and prevention of venous thromboembolism in the general population and patients with oncological diseases
by: A. S. Kolbin, et al.
Published: (2023)

Cost-Effectiveness Analysis of Direct Oral Anticoagulants Versus Vitamin K Antagonists for Venous Thromboembolism in China
by: Ke-Xin Sun, et al.
Published: (2021)

Clinical characteristics and dosing of apixaban and rivaroxaban for the management of venous thromboembolism: A multi-center retrospective observational study
by: Majed S. Al Yami, et al.
Published: (2023)

Apixaban versus enoxaparin to prevent venous thromboembolism in post-operative patients with gynecologic cancers at an urban academic medical center
by: Victoria Diamond, et al.
Published: (2024)

Effect of heparin for the prevention of venous thromboembolism in patients with spontaneous intracranial cerebral hemorrhage: a meta-analysis
by: Yifu Zhou, et al.
Published: (2024)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
by: Pineo GF, et al.
Published: (2012)

Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach
by: Abdel-Razeq H, et al.
Published: (2011)

VENOUS THROMBOEMBOLISM IN RELATION TO OVARIAN HYPERSTIMULATION SYNDROME: AN APPROACH TO DETERMINING THE LOW-MOLECULAR-WEIGHT-HEPARIN DOSES AND ACTIVITY
by: I. E. Zazerskaya, et al.
Published: (2016)

Primary prevention of venous thromboembolism with low molecular weight heparins in surgical patients - 2024: Council of Experts resolution
by: А. S. Petrikov, et al.
Published: (2024)

Transferability of Published Population Pharmacokinetic Models for Apixaban and Rivaroxaban to Subjects with Obesity Treated for Venous Thromboembolism: A Systematic Review and External Evaluations
by: Cyril Leven, et al.
Published: (2023)

PROPHYLAXIS OF VENOUS THROMBOEMBOLIC COMPLICATIONS IN PATIENTS WITH ACTIVE ONCOLOGICAL DISEASE, RECEIVING MEDICAL ANTI-CANCER CHEMOTHERAPY IN OUTPATIENT CONDITIONS. ROLE OF APIXABAN
by: Yu. A. Fedotkina, et al.
Published: (2020)

Dalteparin versus vitamin K antagonists for the prevention of recurrent venous thromboembolism in patients with cancer and renal impairment: a Canadian pharmacoeconomic analysis
by: Dranitsaris G, et al.
Published: (2017)

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015)

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION
by: A. V. Rudakova
Published: (2015)

Chromogenic anti-Xa test: the ratio between heparin activity units and concentration of apixaban and rivaroxaban
by: E. V. Titaeva, et al.
Published: (2020)

Pediatric Venous Thromboembolism
by: Julie Jaffray
Published: (2018)

Preeclampsia and venous thromboembolism
by: K. N. Grigoreva, et al.
Published: (2022)

Neonatal Venous Thromboembolism
by: Kristina M. Haley
Published: (2017)

Budget impact analysis of dexamethasone intravitreal implant for the treatment of diabetic macular oedema
by: Fernando de Andrés-Nogales, et al.
Published: (2018)

Air travel and venous thromboembolism
by: Mendis Shanthi, et al.
Published: (2002)

Review of the cost of venous thromboembolism
by: Fernandez MM, et al.
Published: (2015)

The importante of profilaxis in venous thromboembolism
by: Marcelo Calil Burihan
Published: (2020)

Editorial: Pediatric Venous Thromboembolism
by: Brian R. Branchford, et al.
Published: (2018)

The Role of Inflammation in Venous Thromboembolism
by: Brian R. Branchford, et al.
Published: (2018)

Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants
by: Mariacarla Gallù, et al.
Published: (2020)

Cost-effectiveness analysis of direct oral anticoagulants versus low-molecular-weight heparin and no thromboprophylaxis in primary prevention of cancer-associated venous thromboembolism in China
by: Yue Wu, et al.
Published: (2024)

Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017)

Non-vitamin K oral anticoagulant in the prevention and treatment of venous thromboembolism. Why betrixaban is different?
by: Łukasz Wołowiec, et al.
Published: (2017)

Prevention, diagnosis and treatment of venous thromboembolism
by: Dominik Machaj, et al.
Published: (2020)

Risk factors for venous thromboembolism in women
by: Т. Н. Тутченко, et al.
Published: (2018)